Enveric Biosciences, Inc.
ENVBNASDAQHealthcare● Active
$1.75
$-0.05(-2.78%)
Market Cap$1044771
P/E Ratio—
52W High$17.64
52W Low$1.66
Enveric Biosciences, Inc. (ENVB) Earnings: Dates, EPS & Revenue History
Quarterly EPS vs. estimates, revenue surprises, next earnings date, and analyst consensus.
ENVB · earnings · updated Jun 9, 2026
Latest Earnings
Q2 FY2026Report Date: May 15, 2026EPS Actual
-$1.08
Revenue
—
Fiscal Period
Q2 FY2026
FY ends December
Report Date
May 15, 2026
After Market Close
🔥 4-Quarter EPS Beat Streak
ENVB reports quarterly as a NASDAQ-listed Biotechnology company. Fiscal year ends in December. Data: FMP · Updated hourly.
Next Earnings Date
Days Away
84
days
Expected Date
Sep 1, 2026
Fiscal Period
Q3 FY2026
Release Time
◌ Time TBD (Unconfirmed)EPS Est.
$0.02
Rev. $0.33B
Days Away84
Expected DateSep 1, 2026
Fiscal PeriodQ3 FY2026
Release TimeTime TBD (Unconfirmed)
EPS Est.$0.02
Rev. Est.$0.33B
EPS & Revenue vs. Estimates
Actual (Beat)
Actual (Miss)
Estimated
Earnings History
| Period | Report Date | EPS Est. | EPS Actual | EPS Surpr. | Revenue | Rev. Est. | Rev. Surpr. |
|---|---|---|---|---|---|---|---|
| ◌ Q3 FY2026 | Aug 17, 2026 | — | — | — | — | — | — |
| — Q2 FY2026 | May 15, 2026 | — | -$1.08 | — | — | — | — |
| ▲ Q1 FY2026 | Mar 27, 2026 | -$55.80 | $0.85 | +101.5% | — | — | — |
| ▲ Q4 FY2025 | Nov 14, 2025 | -$63.00 | -$10.81 | +82.8% | — | — | — |
| ▲ Q3 FY2025 | Aug 14, 2025 | -$63.00 | -$11.64 | +81.5% | — | — | — |
| ▲ Q2 FY2025 | May 14, 2025 | -$6.00 | -$1.22 | +79.7% | — | — | — |
| ▼ Q1 FY2025 | Mar 31, 2025 | -$3.45 | -$21.89 | -534.5% | $0.00B | — | — |
| ▲ Q4 FY2024 | Nov 14, 2024 | -$7.80 | -$3.60 | +53.9% | — | — | — |
Q3 FY2026
Aug 17, 2026
EPS Actual
—
EPS Est.
—
EPS Surpr.
—
Revenue
—
Q2 FY2026
May 15, 2026
EPS Actual
-$1.08
EPS Est.
—
EPS Surpr.
—
Revenue
—
Q1 FY2026
Mar 27, 2026Beat
EPS Actual
$0.85
EPS Est.
-$55.80
EPS Surpr.
+101.5%
Revenue
—
Q4 FY2025
Nov 14, 2025Beat
EPS Actual
-$10.81
EPS Est.
-$63.00
EPS Surpr.
+82.8%
Revenue
—
Q3 FY2025
Aug 14, 2025Beat
EPS Actual
-$11.64
EPS Est.
-$63.00
EPS Surpr.
+81.5%
Revenue
—
Q2 FY2025
May 14, 2025Beat
EPS Actual
-$1.22
EPS Est.
-$6.00
EPS Surpr.
+79.7%
Revenue
—
Q1 FY2025
Mar 31, 2025Miss
EPS Actual
-$21.89
EPS Est.
-$3.45
EPS Surpr.
-534.5%
Revenue
$0.00B
Q4 FY2024
Nov 14, 2024Beat
EPS Actual
-$3.60
EPS Est.
-$7.80
EPS Surpr.
+53.9%
Revenue
—
Analyst Estimates
Limited analyst coverage (fewer than 3 analysts). Estimates may not reflect market consensus.
EPS Estimates
| Period | Low | Consensus | High | # Analysts |
|---|---|---|---|---|
| Q4 FY2025 | $-55.80 | $-55.80 | $-55.80 | 1 |
| Q3 FY2025 | $-63.00 | $-63.00 | $-63.00 | 1 |
Revenue Estimates
| Period | Low | Consensus | High | # Analysts |
|---|---|---|---|---|
| Q4 FY2025 | $0.0B | $0.0B | $0.0B | 0 |
| Q3 FY2025 | $0.0B | $0.0B | $0.0B | 0 |
Earnings Price Reaction
Closing price one trading day before vs. one trading day after each earnings release.
| Period | Report Date | EPS Beat/Miss | Price Before | Price After | 1D Reaction |
|---|---|---|---|---|---|
| — Q2 FY2026 | May 15, 2026 | — | $2.29 | $2.25 | -1.75% |
| ▲ Q1 FY2026 | Mar 27, 2026 | +101.5% | $1.86 | $1.88 | +1.08% |
| ▲ Q4 FY2025 | Nov 14, 2025 | +82.8% | $5.46 | $5.28 | -3.30% |
| ▲ Q3 FY2025 | Aug 14, 2025 | +81.5% | $13.32 | $13.32 | +0.00% |
| ▲ Q2 FY2025 | May 14, 2025 | +79.7% | $17.16 | $15.72 | -8.39% |
| ▼ Q1 FY2025 | Mar 31, 2025 | -534.5% | $17.64 | $16.68 | -5.44% |
| ▲ Q4 FY2024 | Nov 14, 2024 | +53.9% | $73.44 | $71.52 | -2.61% |
| ▲ Q3 FY2024 | Aug 12, 2024 | +54.5% | $99.00 | $94.44 | -4.61% |
Q2 FY2026-1.75%
Report Date
May 15, 2026
EPS Beat/Miss
—
Price Before
$2.29
Price After
$2.25
Q1 FY2026+1.08%
Report Date
Mar 27, 2026
EPS Beat/Miss
+101.5%
Price Before
$1.86
Price After
$1.88
Q4 FY2025-3.30%
Report Date
Nov 14, 2025
EPS Beat/Miss
+82.8%
Price Before
$5.46
Price After
$5.28
Q3 FY2025+0.00%
Report Date
Aug 14, 2025
EPS Beat/Miss
+81.5%
Price Before
$13.32
Price After
$13.32
Q2 FY2025-8.39%
Report Date
May 14, 2025
EPS Beat/Miss
+79.7%
Price Before
$17.16
Price After
$15.72
Q1 FY2025-5.44%
Report Date
Mar 31, 2025
EPS Beat/Miss
-534.5%
Price Before
$17.64
Price After
$16.68
Q4 FY2024-2.61%
Report Date
Nov 14, 2024
EPS Beat/Miss
+53.9%
Price Before
$73.44
Price After
$71.52
Q3 FY2024-4.61%
Report Date
Aug 12, 2024
EPS Beat/Miss
+54.5%
Price Before
$99.00
Price After
$94.44
Avg Beat Reaction-2.97%
Avg Miss Reaction-5.44%
Beat Rate6 / 8 quarters
Largest Move-8.39% (Q2 FY2025)
Data: FMP /historical-price-eod/full · field: close
About Earnings & Data Methodology
Data source: Financial Modeling Prep (FMP) | Updated: Hourly | Surprise%: (Actual − Estimate) / |Estimate| × 100 | Fiscal year: ENVB ends December
Enveric Biosciences, Inc. (ENVB) most recently reported earnings on May 15, 2026 for Q2 FY2026, posting EPS of $-1.08 (in line with the analyst consensus of —). ENVB has beaten EPS estimates for 4 consecutive quarters. The next ENVB earnings date is expected around September 1, 2026.
Each quarter, investors track ENVB earnings for signals on forward guidance and business momentum. For longer-term revenue trends, see the Revenue tab. ENVB revenue tab →
Earnings Glossary
EPS (Earnings Per Share)
Net income ÷ diluted shares outstanding. The primary metric analysts use to gauge quarterly profitability.
Earnings Surprise %
(Actual − Estimate) / |Estimate| × 100. Positive = Beat. Negative = Miss.
Beat / Miss / In-Line
Beat = Actual ≥ Estimate. Miss = Actual < Estimate. In-Line = within ±1%.
BMO / AMC
Before Market Open / After Market Close. Two windows when companies typically release results.
Fiscal Quarter
ENVB's fiscal year ends in December. Fiscal quarters may not align with calendar quarters.
Analyst Consensus
Average EPS/Revenue forecast across all covering analysts. More analysts = more reliable estimate.
Figures tie to FMP earnings calendar, estimates, and SEC 10-Q/10-K filings where noted.
Frequently asked questions
ENVB earnings · 4 questionsEnveric Biosciences, Inc.'s next earnings report is expected around September 1, 2026. ENVB typically reports quarterly — approximately every three months. The exact date is confirmed by the company 2–4 weeks before the release. Time is currently TBD; ENVB historically reports after market close (AMC).
ENVB earnings datewhen is ENVB earningsENVB next earnings datewhen does ENVB report earningsENVB earnings calendar
▸ Source: FMP · Enveric Biosciences, Inc. SEC filings · US GAAP · Enveric Biosciences, Inc. SEC 10-K & 10-Q filings · US GAAP · Updated: Jun 9, 2026